1. Introduction {#sec1}
===============

Preoperative staging of patients with malignant lung cancer suggests the prognosis and the life quality afterwards. An accurate clinical staging can guide physicians to choose a proper treatment according to the authorized guideline and therefore standardizes the management procedure. Especially for those with positive mediastinal lymph nodes (N2 disease), preoperative chemotherapy is reported to reduce tumor size by 25% \[[@B1]\], downstage nearly half of the N2-positive patients \[[@B2]--[@B6]\], and increase the 5-year survival rate of 5-20% compared with surgery alone \[[@B7]--[@B11]\]. In that case, the accuracy of TNM staging before surgery is of paramount important.

The European Society of Thoracic Surgeons (ESTS) guidelines compared the diagnostic accuracy of different preoperative examinations for lymph node evaluation. Computed tomography is common and available in most countries, despite its low sensitivity (55%) and specificity (81%) \[[@B12], [@B13]\]. PET-CT scan is reported to be superior to CT in mediastinal lymph node staging and exhibits a high negative predictive value (NPV) for peripheral tumors. The sensitivity of PET-CT is 80-90%, and the specificity is 85-95% \[[@B12], [@B13]\]. However, PET-CT requires more expensive facilities and is not as popularized as CT. Besides, the negative predictive value of PET-CT decreases in patients with central tumors, tumors \> 3 cm, and suspected N1 metastasis \[[@B12]\].

Reported data shows the prevalence of occult N2 disease in patients with clinical stage I NSCLC is about 5.0-6.5% \[[@B14], [@B15]\]. In order not to omit this part of patients, a predictive model in combination of assisted examination is needed and previous efforts have been made by researchers. In this study, we aim to analyze the clinical features of patients with lymph node metastasis and create a predicted formula of N2 metastasis for clinical T1 lung cancers.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

We retrospectively reviewed patients who were diagnosed with lung cancer and underwent radial surgical recession in Second Affiliated Hospital of Zhejiang University (SAHZU) during 2011-2016. Patients with a malignant nodule within 3 centimeters on CT (staged as cT1) were selected, all of which underwent lymph node evaluation via surgical operation. The exclusion criteria were as follows: (1) patients with multiple pulmonary cancers or metastatic pulmonary nodules, (2) patients with a history of preoperative therapy, and (3) patients without CT scan images before surgery. Patients from 2011 to 2015 were enrolled in the development group (*n* = 924), while patients from 2016 were included in the validation group (*n* = 380), as shown in [Figure 1](#fig1){ref-type="fig"}. This study was approved by the Institutional Ethics of Committee of SAHZU (2017-031).

2.2. Clinicopathological Variables {#sec2.2}
----------------------------------

All the clinicopathological information was collected in the hospital information system (HIS). Information included gender, age, symptoms at presentation, smoking history, smoking index, chronic pulmonary diseases, cancer history, family history of cancer, levels of tumor markers within one month before surgery, histological type of lung cancer, pathological report of resected lymph nodes, tumor location (upper/middle/lower lobe, central/peripheral location), tumor size, consolidation size, C/T ratio (consolidation size/tumor size), and clinical N stage based on CT. Chronic pulmonary diseases included chronic bronchitis, emphysema, and chronic obstructive pulmonary disease (COPD). Tumor size was measured as the largest dimension on CT section in pulmonary window while consolidation size was measured in mediastinal window. Tumors were defined as peripherally located if the center of tumor mass was in the outer one-thirds of pulmonary parenchyma and otherwise as centrally located. A lymph node was considered an enlarged one when its short axis exceeded 1 cm. The seventh edition of TNM classification was referred to in this study.

2.3. Data Analysis {#sec2.3}
------------------

All the continuous variables were described with means and standard deviations, while categorical variables were described with frequencies. In univariate analysis, we performed one-way analysis of variance for continuous variables and Pearson\'s chi-square tests (adjusted *p* values using Bonferroni method) for categorical variables. Significant variables in the univariate analysis were further analyzed in multivariate analysis using polytomous logistic regression, in order to estimate different risk factors and odds ratios for each N stage (pN0, pN1, and pN2).

The dichotomous logistic regression was performed to build a predictive model for N2 metastasis, since N2 metastasis is worse in TNM staging and requires different preoperative treatment strategies. All variables collected from HIS were analyzed with forward stepwise selection, which was based on statistics of a conditional likelihood ratio test. A significant *p* value for entering variables was 0.05, and the *p* value for excluding variables was 0.10. The optimal cutoff point of the model was set according to the highest Youden\'s index. A nomogram was developed using the package of rms based on the logistic regression. In addition, calibration of the model was established with the Hosmer-Lemeshow goodness-of-fit test as well as the calibration curve, and the discrimination ability of the model was assessed by receiver operating characteristic (ROC) analysis. The DeLong test was performed for the comparison of different ROC curves.

All statistical analysis was performed using SPSS Statistics 22.0 (IBM Armonk, NY, USA), EmpowerStats software (X&Y Solutions, Boston, USA, <http://www.empowerstats.com/>), and R 3.5.2 software (R Foundation for Statistical Computing, Vienna, Austria). We considered the differences as statistically significant when two-sided *p* values were less than 0.05.

3. Results {#sec3}
==========

3.1. Clinicopathological Characteristics for Patients in the Development Group {#sec3.1}
------------------------------------------------------------------------------

The clinicopathological characteristics of 924 patients in the development group are shown in [Table 1](#tab1){ref-type="table"}. Patients were at a mean age of 59.1 ± 9.7, and tumor sizes were 1.70 ± 0.62 cm on average. The incidence for lymph node metastasis was 10.82% (100/924), with N1 metastasis being 3.24% (30/924) and N2 metastasis being 7.58% (70/924).

In univariate analysis ([Table 1](#tab1){ref-type="table"}), lymph node metastasis was prone to be found in smoking males who suffered from chronic pulmonary diseases and were hospitalized with respiratory- or cancer-related symptoms (RCRS) and higher levels of carcinoembryonic antigen (CEA). Tumors with larger size (or consolidation size), central location, and lymph node enlargement on CT images were associated with higher likelihood of lymph node metastasis. Besides, patients with squamous carcinoma were more likely to have N1 metastasis, while N2 metastasis in patients with adenocarcinoma was three times more likely to occur than N1 metastasis.

3.2. Odds Ratios of N1 and N2 Metastases versus N0 Status {#sec3.2}
---------------------------------------------------------

In polytomous logistic regression ([Table 2](#tab2){ref-type="table"}), significant variables in univariate analysis were further analyzed to estimate the risk factors and odds ratios of nodal metastasis stratified by the 7^th^ TNM staging. Significantly elevated odds ratios were seen in tumors with larger consolidation size and lymph node enlargement on CT for N1 metastasis (OR~consolidation size~ = 5.449, 95% CI: 2.817-10.541; OR~lymph node enlargement on CT~ = 11.424, 95% CI: 3.316-39.360) and N2 metastasis (OR~consolidation size~ = 8.640, 95% CI: 5.002-14.923; OR~lymph node enlargement on CT~ = 8.703, 95% CI: 4.326-17.509) compared to N0 status. A significantly decreased odds ratio was seen in smokers for N2 metastasis (OR~smoking history~ = 0.217, 95% CI: 0.080-0.590) compared to N0 status in nonsmokers. Tumors with a central location seemed to have a negative correlation with N2 metastasis though there was no significant difference.

3.3. Logistic Regression Model and Predictors of N2 Metastasis {#sec3.3}
--------------------------------------------------------------

Dichotomous logistic regression identified five independent predictors for N2 metastasis: peripheral location, consolidation size, lymph node enlargement on CT, no smoking history, and levels of serum CEA ([Table 3](#tab3){ref-type="table"}). Gender, histological type, and C/T ratio were not involved as significant factors. The formula predicting N2 metastasis for small tumor nodules was established: *e*^*x*^/(1 + *e*^*x*^), *x* = −0.756^×^central location + 1.921^×^consolidation size + 2.145^×^lymph node enlargement on CT − 1.065^×^smoking history + 0.064^×^CEA level − 6.165. The unit for "consolidation size" is cm and for "CEA level" is ng/ml. The value of "lymph node enlargement on CT," "central location," and "smoking history" should be 1 for yes and otherwise 0. A nomogram predicting the probability for N2 metastasis in cT1 patients was developed on the basis of multivariate logistic analysis ([Figure 2](#fig2){ref-type="fig"}).

The Hosmer-Lemeshow goodness-of-fit test, which was not statistically significant (*p* = 0.839), indicated that the predicted probability was of high concordance to the observed probability. A calibration curve is shown in [Figure 3](#fig3){ref-type="fig"}. The area under the receiver operating characteristic curve was 0.931, with 95% confidence interval between 0.906 and 0.955 ([Figure 4(a)](#fig4){ref-type="fig"}). We selected the numerical value with the highest Youden\'s index as our cutoff point for the predicted probability (cutoff for probability = 7.43%).

3.4. Validation of the Model and Comparison with Previous Models {#sec3.4}
----------------------------------------------------------------

The characteristics of patients in the validation group were shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}. In the external validation, the AUC of our model was 0.906 (95% CI: 0.857-0.956, [Figure 4(b)](#fig4){ref-type="fig"}). With the cutoff point set above (cutoff = 7.43%), we tested our model in the validation group. The sensitivity and specificity were 60.0% and 90.3%, respectively. The negative and positive predictive values (NPV and PPV) were 97.6% and 25.5%, respectively. In a subgroup analysis of adenocarcinoma (ADC) and squamous cell carcinoma (SCC), the validated AUC of ADC patients was 0.856 (95% CI: 0.790-0.922) and the validated AUC of SCC patients was 0.864 (95% CI: 0.777-0.952) (*p* = 0.885, DeLong test).

We also compared our model with the Fudan model \[[@B16]\] and Beijing model \[[@B17]\], as all three studies included clinical T1 NSCLC. Analyzed with all the data from our validation group, the validated AUC of the Beijing model was 0.879 (95% CI: 0.821-0.937) compared with 0.906 (95% CI: 0.857-0.956) of our model (*p* = 0.405, DeLong test). Based on the inclusion criteria of the Fudan model, patients with cT1N0M0 lung cancers were selected from the validation group of our study. And the validated AUC of the Fudan model was 0.712 (95% CI: 0.602-0.822) while the AUC of our model was 0.885 (95% CI: 0.820-0.949) (*p* = 0.002, DeLong test). Our model showed a larger area under the ROC curve compared to other models ([Figure 5](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

Lymph node status, especially the assessment of N2 metastasis, largely affects the treatment strategies in the clinic. Therefore, it is of great significance to make an accurate and noninvasive assessment of lymph nodes before operation. In this study, we established a five-variable formula predicting N2 metastasis for malignant nodules within 3 cm. Our model showed a high negative predictive value of 97.6% and specificity of 90.3%, which can select patients with low risks of N2 metastasis and help with the clinical decision-making.

As a truly multidisciplinary process, preoperative evaluation of lymph node evaluation has confused clinical physicians for many years. An algorithm that integrates imaging, endoscopic, and surgical techniques recommended by ESTS guidelines has been widely practiced and prospectively validated, with the negative predictive value as high as 0.94 \[[@B18]\]. However, some researchers are more interested in creating a predictive model ahead of biopsy strategy \[[@B16], [@B17], [@B19]--[@B21]\], because the accuracy of preoperative invasive staging such as TBNA may largely depend on the experience of operators.

Shafazand and Gould reported the first quantitative model to pretest the probability for N2 metastasis in NSCLC of all stages \[[@B20]\]. The formula consisted of six independent predictors, which were age, tumor size, central location, adenocarcinoma histology, onset of primary symptoms, and abnormal mediastinum on chest X-ray. However, their data was directly collected from a previous randomized controlled trial and no CT images were included at that time. After that, Zhang and colleagues reported a four-predictor model for N2 metastasis in CT-defined T1N0M0 NSCLC in 2012 \[[@B16]\]. Younger patients with a central-located and larger-sized lung adenocarcinoma had higher risks of N2 disease. However, patients with a histology of AIS (adenocarcinoma in situ) and MIA (microinvasive adenocarcinoma) were excluded from their study, despite the fact that the pathology of AIS or MIA could only be confirmed from a resected specimen. In that case, the percentage of adenocarcinoma might be underestimated in their model because there will be AIS and MIA patients in reality. More recently, there were predictive models evaluating N2 metastasis for NSCLC of all stages \[[@B21]\] and models estimating nodal metastasis in clinical T1a stages \[[@B17]\].

No models above have referred to the different risk factors of N1 and N2 metastases. Analyzed by polytomous logistic regression, we found that consolidation tumor size and lymph node enlargement on CT scan were the most related factors to both N1 and N2 metastases in patients with early malignant nodules (diameter ≤ 3 cm, stage T1). Though it is difficult to differentiate benign lymphadenectasis from lymph node metastasis on CT, our results showed that lymphadenectasis in N1 station was of higher correlation to N2 metastasis. This could be explained by the lymphatic drainage, and the rate for skip N2 metastasis was only 29% \[[@B22]\]. This result was partly in accordance with the previous literature and the ESTS recommendation \[[@B13], [@B23]\].

In both polytomous and dichotomous logistic analyses, consolidation tumor size and lymph node enlargement on CT and CEA levels were correlated to N2 metastasis, which is consistent with previous studies \[[@B16], [@B17], [@B24], [@B25]\]. Smoking history seemed to be negatively associated with N2 disease, as the odds ratio was less than 1 in both analyses. Despite the lack of molecular mechanisms, nonsmokers are more prone to a delayed or incidental detection of lung cancer than smokers and thus are more likely to progress into nodal metastasis, as supported by data from Lee et al. \[[@B26]\]. Apart from that, tumors with peripheral location were found with a higher likelihood of N2 metastasis in this study. The inconsistency between different research studies \[[@B27], [@B28]\] could result from the different criteria of the definition as "central location" and the different target population. Takeda et al. also found that peripheral tumors are more likely to have N2 metastasis by subpleural lymph drainage pathways \[[@B29]\].

Compared with previous logistic analysis, this study exhibited a larger sample size and reduced selective bias by enrolling patients with all pathological type including AIS and MIA, which constituted 8.2% and 16.7% of ground-glass nodules in the development group. Our data suggested that consolidation size was a stronger predictive factor of nodal metastasis compared with tumor size and C/T ratio in the multivariate analysis. Squamous cell carcinoma also fit in with this model though it was a minority type of histology. Besides, pathological type was not an independent factor in this multivariate model, suggesting that preoperative histology might not be a necessity for predicting N2 metastasis.

Nevertheless, this study also had several limitations. Firstly, it was a retrospective study and there was no standard on the number of resected lymph nodes. In 2014, American College of Surgeons Commission on Cancer recommended at least 10 regional lymph nodes to be removed and pathologically examined for resectable NSCLC \[[@B30]\]. Thus, a diagnostic bias might occur in our study. Secondly, we only collected data from a single-center institution and reflected patient characteristics in local areas. Finally, in order to ensure the general use of the model, the proportion of lymph node metastasis in this study was coherent with the prevalence in reality, which was insufficient and influenced the positive predictive value of the model. Therefore, a larger-sized study with more positive data from multiple medical centers will be needed to carry out a more practical model for clinical use.

5. Conclusions {#sec5}
==============

In this study, we analyzed the clinical features of patients with lymph node metastasis and produced a model predicting the possibility of N2 nodal metastasis for early lung cancers (tumor ≤ 3 cm). Stratified by the cutoff point, a low predicted probability may suggest an operation directly without neoadjuvant therapies, while a relatively high predicted probability needs support from further invasive and expensive examinations. Our model will provide some clues for clinical decision-making.
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![Flowchart of patient selection and exclusion.](JIR2019-6263249.001){#fig1}

![Nomogram predicting the likelihood of N2 metastasis in early lung cancers (tumor ≤ 3 cm). According to the location of value from the 2nd to the 6th axis, we can get the vertically corresponding points on the first axis. By summing up each points, we get a total point, and the vertically corresponding predicted value on the last axis shows the predicted possibility of N2 metastasis.](JIR2019-6263249.002){#fig2}

![Calibration curve of the logistic regression model. The red line indicated a perfect prediction of observed possibilities. The black line represented the entire development group (*n* = 924).](JIR2019-6263249.003){#fig3}

![The receiver operating characteristic curve for the development and validation groups. (a) The ROC curve for the development group. The AUC was 0.931 (95% CI: 0.906-0.955). (b) The ROC curve for the validation group. The AUC was 0.906 (95% CI: 0.857-0.956).](JIR2019-6263249.004){#fig4}

![Comparison of our model and other published models using data from the same validation group. (a) Comparison with Zang et al. (2017) in cT1NxM0 patients. The AUC was 0.879 validated by our data (95% CI: 0.821-0.937). DeLong test for comparing two ROC curves: *p* = 0.405. (b) Comparison of our model with Zhang et al. (2012) in cT1N0M0 patients. The AUC was 0.712 validated by our data (95% CI: 0.602-0.822). DeLong test for comparing two ROC curves: *p* = 0.002.](JIR2019-6263249.005){#fig5}

###### 

Characteristics of patients in the development group.

                                Patients with negative LNs (%)   Patients with positive N1 nodes (%)   Patients with positive N2 nodes (%)   *p* value^∗^
  ----------------------------- -------------------------------- ------------------------------------- ------------------------------------- --------------
  Age (year)                    59.1 ± 9.7                       58.1 ± 10.0                           58.9 ± 10.4                           0.742
  Gender                                                                                                                                     
   Male                         346 (85.4)                       21 (5.2)                              38 (9.4)                              0.011
   Female                       478 (92.1)                       9 (1.7)                               32 (6.2)                              
  Symptoms                                                                                                                                   
   RCE                          456 (91.9)                       8 (1.6)                               32 (6.5)                              0.010
   RCRS                         256 (85.6)                       16 (5.4)                              27 (9.0)                              
   ICD                          112 (86.8)                       6 (4.7)                               11 (8.5)                              
   Asymptomatic                 568 (90.9)                       14 (2.2)                              43 (6.9)                              0.008
   Symptomatic                  256 (85.6)                       16 (5.4)                              27 (9.0)                              
  Cancer history                                                                                                                             
   Yes                          58 (85.3)                        4 (5.9)                               6 (8.8)                               0.454
   No                           766 (89.5)                       26 (3.0)                              64 (7.5)                              
  Family history of cancer                                                                                                                   
   Yes                          122 (91.0)                       1 (0.8)                               11 (8.2)                              0.169
   No                           702 (88.9)                       29 (3.7)                              59 (7.4)                              
  Pathology                                                                                                                                  
   Adenocarcinoma               760 (91.2)                       16 (1.9)                              57 (6.9)                              \<0.001
   Squamous                     52 (75.4)                        10 (14.5)                             7 (10.1)                              
   Adenosquamous                3 (37.5)                         1 (12.5)                              4 (50.0)                              
   Neuroendocrine               8 (66.7)                         3 (25.0)                              1 (8.3)                               
   Other tumor type             1 (50.0)                         0 (0.0)                               1 (50.0)                              
  Smoking history                                                                                                                            
   Yes                          220 (85.3)                       17 (6.6)                              21 (8.1)                              0.001
   No                           604 (90.7)                       13 (2.0)                              49 (7.3)                              
  Location                                                                                                                                   
   Upper lobe                   445 (90.1)                       14 (2.8)                              35 (7.1)                              0.670
   Lower lobe                   270 (88.8)                       9 (3.0)                               25 (8.2)                              
   Middle lobe                  109 (86.5)                       7 (5.6)                               10 (7.9)                              
   Central                      316 (86.6)                       18 (4.9)                              31 (8.5)                              0.042
   Peripheral                   508 (90.9)                       12 (2.1)                              39 (7.0)                              
  Nodule size on CT                                                                                                                          
   Tumor size (cm)              1.63 ± 0.59                      2.25 ± 0.57                           2.33 ± 0.50                           \<0.001
   Consolidation size (cm)      0.91 ± 0.83                      2.19 ± 0.69                           2.22 ± 0.59                           \<0.001
   C/T ratio                    0.51 ± 0.41                      0.95 ± 0.19                           0.95 ± 0.15                           \<0.001
  Chronic pulmonary disease                                                                                                                  
   Yes                          68 (78.2)                        8 (9.2)                               11 (12.6)                             0.001
   No                           756 (90.3)                       22 (2.6)                              59 (7.1)                              
  Clinical nodal stage on CT                                                                                                                 
   Enlarged LNs in N2 station   72 (64.3)                        7 (6.3)                               33 (29.4)                             \<0.001
   Enlarged LNs in N1 station   10 (38.5)                        6 (23.0)                              10 (38.5)                             
   Normal-sized LNs             742 (94.4)                       17 (2.2)                              27 (3.4)                              
  Levels of tumor markers                                                                                                                    
   CEA (ng/ml)                  3.26 ± 4.84                      3.55 ± 2.56                           10.21 ± 17.58                         \<0.001
   AFP (ng/ml)                  3.03 ± 1.80                      2.68 ± 0.89                           3.25 ± 2.71                           0.542
   CA199 (U/ml)                 10.48 ± 15.24                    9.99 ± 9.26                           15.67 ± 17.16                         0.013
   CA125 (U/ml)                 11.31 ± 11.22                    13.23 ± 10.04                         26.53 ± 77.33                         0.093
   CA242 (U/ml)                 5.42 ± 4.34                      4.80 ± 3.22                           5.54 ± 3.31                           0.996
   CA211 (ng/ml)                1.12 ± 0.84                      1.49 ± 1.07                           1.36 ± 1.01                           0.006
   NSE (ng/ml)                  9.58 ± 4.55                      8.48 ± 4.87                           9.99 ± 5.32                           0.793
   SCC (ng/ml)                  0.84 ± 0.83                      1.15 ± 0.78                           0.93 ± 0.59                           0.143

RCE: routine chest examination; RCRS: respiratory- or cancer-related symptoms; ICD: incidental chest discovery; C/T ratio: consolidation size/tumor size ratio. ^∗^*p* value acquired from one-way analysis of variance and Pearson\'s chi-square tests.

###### 

Odds ratios of likelihood of lymph node metastasis stratified by seventh TNM staging using polytomous logistic regression.

  Variable                                  N1 metastasis (*n* = 30)   N2 metastasis (*n* = 70)                           
  ----------------------------------------- -------------------------- -------------------------- ----------------------- ---------
  Male gender                               2.366 (0.726-7.707)        0.153                      2.019 (0.868-4.697)     0.103
  Chronic pulmonary disease                 1.827 (0.665-5.021)        0.242                      1.231 (0.489-3.102)     0.659
  Smoking history                           0.479 (0.138-1.663)        0.246                      0.217 (0.080-0.590)     0.003
  Respiratory- or cancer-related symptoms   1.558 (0.692-3.508)        0.284                      0.741 (0.374-1.467)     0.389
  Adenocarcinoma histology                  1.742 (0.619-4.901)        0.293                      0.849 (0.330-2.181)     0.733
  Consolidation size (cm)                   5.449 (2.817-10.541)       \<0.001                    8.640 (5.002-14.923)    \<0.001
  Central location                          1.069 (0.448-2.547)        0.881                      0.508 (0.255-1.014)     0.055
  Clinical nodal stage on CT                                                                                              
   Enlarged LNs in N1 station               11.424 (3.316-39.360)      \<0.001                    14.046 (4.226-46.682)   \<0.001
   Enlarged LNs in N2 station               1.615 (0.582-4.480)        0.357                      8.703 (4.326-17.509)    \<0.001
  Levels of serum CEA (ng/ml)               0.932 (0.806-1.077)        0.340                      1.063 (1.027-1.099)     0.001

^\#^ *p* value represented the comparison with N0 patients.

###### 

Multivariate dichotomous logistic regression of the development group for predicting N2 metastasis.

  Variable                     Regression coefficient   *p* value   Odds ratio   95% confidence interval   
  ---------------------------- ------------------------ ----------- ------------ ------------------------- --------
  Central location             -0.756                   0.029       0.469        0.239                     0.924
  Consolidation size (cm)      1.921                    \<0.001     6.824        4.095                     11.373
  Enlarged lymph node on CT    2.145                    \<0.001     8.546        4.491                     16.262
  Smoking history              -1.065                   0.003       0.345        0.169                     0.704
  Level of serum CEA (ng/ml)   0.064                    \<0.001     1.066        1.031                     1.102

[^1]: Guest Editor: Kong Chen
